Evidence map›Paper›PMID 42495265›Full record

ArticleLancet regional health. Americas2026

Measuring the health benefits and costs of antimicrobial-resistant gonorrhea surveillance in the United States: an agent-based model and cost-effectiveness analysis.

Marcy S Ekanayake-Weber, Minttu M Rönn, Xuecheng Yin, Katherine Hsu, Yunfei Li, Thomas L Gift, Harrell Chesson, Rebekah Frankson, Joshua A Salomon, Yonatan H Grad and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marcy S Ekanayake-WeberDepartment of Anthropology, University at Albany, Albany NY 12222, USA.
Minttu M RönnDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA.
Xuecheng YinDepartment of Management Science and Information Systems, Spears School of Business, Oklahoma State University, Stillwater, OK 74078, USA.
Katherine HsuMassachusetts Department of Public Health, Boston, MA 02108, USA.
Yunfei LiDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA.
Thomas L GiftDivision of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Harrell ChessonDivision of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Rebekah FranksonDivision of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Joshua A SalomonDepartment of Health Policy, Stanford University School of Medicine, Stanford, CA 94305, USA.
Yonatan H GradDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA.
Reza YaesoubiDepartment of Health Policy and Management, Yale School of Public Health, New Haven, CT 06511, USA.

Funding

Enhancing surveillance systems to slow the spread of antimicrobial-resistant gonorrhea in the United StatesR01AI153351 · NIAID · YALE UNIVERSITY · PI YAESOUBI, REZA · 2020 to 2024
$2.1M
NIAID NIH HHS R01 AI153351
6 · The paper itself

Abstract

Background: Antimicrobial resistant (AMR) gonorrhea poses an increasing threat to public health, yet evidence on the cost-effectiveness of surveillance systems that inform treatment policy is lacking. We assessed the long-term, population-level health benefits, costs, and cost-effectiveness of the Gonococcal Isolate Surveillance Project (GISP), the US national surveillance system for AMR gonorrhea. Methods: We developed an agent-based model of gonococcal transmission among men who have sex with men to project gonorrhea-associated costs (healthcare sector perspective) and quality-adjusted life-years (QALYs) lost under GISP and three hypothetical scenarios in the absence of GISP: Randomized Treatment, Test-of-Cure, and a Combination strategy, representing a combination of clinical strategies for treating gonorrhea. Findings: Over 20 years in a population of 100,000 men who have sex with men, all strategies resulted in similar overall gonorrhea incidence, but GISP achieved the lowest treatment failure incidence (1852 vs. 86,526, 144,063, and 119,258) and lowest AMR gonorrhea incidence (105,564 vs. 530,854, 631,123, and 575,309 infections). GISP resulted in lower costs and QALYs compared with each of the counterfactual strategies considered in our analysis. Interpretation: Our findings highlight the health and economic benefits of GISP in controlling AMR gonorrhea and can be an efficient use of public health resources in the US. Additional studies are required to investigate the generalizability of our findings for other countries. Funding: National Institutes of Health.

Indexed as

Agent-based modelAntimicrobial resistanceMSMNeisseria gonorrhoeaeSexually transmitted infection

Identifiers

PMID42495265
PMCPMC13392961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.